Results of an overall survival analysis of A+AVD as compared with ABVD from the ECHELON-1 trial, as well as long-term safety data, after approximately 6 years of follow-up were reported by Ansell et al in The New England Journal of Medicine.
Question 1 of 5
Patients in the ECHELON-1 study were assigned to receive brentuximab vedotin as part of one of two treatment regimens: A+AVD (investigational regimen) or ABVD (standard therapy). Which of the following treatments is not in the investigational regimen?
